U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Fallopian Tube Carcinoma

MedGen UID:
1669538
•Concept ID:
C4726622
•
Neoplastic Process
Synonym: Refractory Fallopian Tube Cancer

Definition

Fallopian tube carcinoma that is resistant to treatment. [from NCI]

Professional guidelines

PubMed

Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer.
Kobayashi-Kato M, Yunokawa M, Bun S, Miyasaka N, Kato T, Tamura K
Cancer Chemother Pharmacol 2019 Jul;84(1):33-39. Epub 2019 Apr 13 doi: 10.1007/s00280-019-03834-1. PMID: 30982097
Treatment Patterns and Health Outcomes in Platinum-Refractory or Platinum-Resistant Ovarian Cancer: A Retrospective Medical Record Review.
Parikh R, Kurosky SK, Udall M, Chang J, Cappelleri JC, Doherty JP, Kaye JA
Int J Gynecol Cancer 2018 May;28(4):738-748. doi: 10.1097/IGC.0000000000001222. PMID: 29538247
Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers.
Goto T, Takano M, Ohishi R, Iwasa N, Shimizu M, Hasegawa K, Nagao S, Fujiwara K
J Obstet Gynaecol Res 2010 Aug;36(4):764-8. doi: 10.1111/j.1447-0756.2010.01217.x. PMID: 20666942

Recent clinical studies

Etiology

ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.
Herzog TJ, Hays JL, Barlin JN, Buscema J, Cloven NG, Kong LR, Tyagi NK, Lanneau GS, Long BJ, Marsh RL, Seward SM, Starks DC, Welch S, Moore KN, Konstantinopoulos PA, Gilbert L, Monk BJ, O'Malley DM, Chen X, Dalal R, Coleman RL, Sehouli J
Future Oncol 2023 Jul;19(23):1577-1591. Epub 2023 Jun 19 doi: 10.2217/fon-2023-0246. PMID: 37334673
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, Richardson GE, Sessa C, Yonemori K, Banerjee S, Leary A, Tinker AV, Jung KH, Madry R, Park SY, Anderson CK, Zohren F, Stewart RA, Wei C, Dychter SS, Monk BJ
Lancet Oncol 2021 Jul;22(7):1034-1046. Epub 2021 Jun 15 doi: 10.1016/S1470-2045(21)00216-3. PMID: 34143970
Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.
Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, Liu S, Akers S, Lele S, Frederick PJ, Odunsi K
JAMA Oncol 2021 Jan 1;7(1):78-85. doi: 10.1001/jamaoncol.2020.5945. PMID: 33211063Free PMC Article
Personalized cancer treatment for ovarian cancer.
Chumworathayi B
Asian Pac J Cancer Prev 2013;14(3):1661-4. doi: 10.7314/apjcp.2013.14.3.1661. PMID: 23679252
Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials.
Markman M, Webster K, Zanotti K, Peterson G, Kulp B, Belinson J
Gynecol Oncol 2004 Jun;93(3):699-701. doi: 10.1016/j.ygyno.2004.03.023. PMID: 15196867

Diagnosis

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, Richardson GE, Sessa C, Yonemori K, Banerjee S, Leary A, Tinker AV, Jung KH, Madry R, Park SY, Anderson CK, Zohren F, Stewart RA, Wei C, Dychter SS, Monk BJ
Lancet Oncol 2021 Jul;22(7):1034-1046. Epub 2021 Jun 15 doi: 10.1016/S1470-2045(21)00216-3. PMID: 34143970
Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.
Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, Liu S, Akers S, Lele S, Frederick PJ, Odunsi K
JAMA Oncol 2021 Jan 1;7(1):78-85. doi: 10.1001/jamaoncol.2020.5945. PMID: 33211063Free PMC Article
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ
Lancet Oncol 2019 May;20(5):636-648. Epub 2019 Apr 1 doi: 10.1016/S1470-2045(19)30029-4. PMID: 30948273
The current treatment of recurrent ovarian cancer.
Herzog TJ
Curr Oncol Rep 2006 Nov;8(6):448-54. doi: 10.1007/s11912-006-0074-9. PMID: 17040623
Resection of recurrent ovarian or fallopian tube carcinoma involving the liver.
Yoon SS, Jarnagin WR, Fong Y, DeMatteo RP, Barakat RR, Blumgart LH, Chi DS
Gynecol Oncol 2003 Nov;91(2):383-8. doi: 10.1016/j.ygyno.2003.07.005. PMID: 14599870

Therapy

ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.
Herzog TJ, Hays JL, Barlin JN, Buscema J, Cloven NG, Kong LR, Tyagi NK, Lanneau GS, Long BJ, Marsh RL, Seward SM, Starks DC, Welch S, Moore KN, Konstantinopoulos PA, Gilbert L, Monk BJ, O'Malley DM, Chen X, Dalal R, Coleman RL, Sehouli J
Future Oncol 2023 Jul;19(23):1577-1591. Epub 2023 Jun 19 doi: 10.2217/fon-2023-0246. PMID: 37334673
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
Joerger M, Hundsberger T, Haefliger S, von Moos R, Hottinger AF, Kaindl T, Engelhardt M, Marszewska M, Lane H, Roth P, Stathis A
Invest New Drugs 2023 Apr;41(2):267-275. Epub 2023 Feb 16 doi: 10.1007/s10637-023-01336-9. PMID: 36792805Free PMC Article
Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.
Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, Liu S, Akers S, Lele S, Frederick PJ, Odunsi K
JAMA Oncol 2021 Jan 1;7(1):78-85. doi: 10.1001/jamaoncol.2020.5945. PMID: 33211063Free PMC Article
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ
Lancet Oncol 2019 May;20(5):636-648. Epub 2019 Apr 1 doi: 10.1016/S1470-2045(19)30029-4. PMID: 30948273
Personalized cancer treatment for ovarian cancer.
Chumworathayi B
Asian Pac J Cancer Prev 2013;14(3):1661-4. doi: 10.7314/apjcp.2013.14.3.1661. PMID: 23679252

Prognosis

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
Effectiveness of oral etoposide in recurrent or refractory epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.
Kongsawatvorakul C, Charakorn C, Chittithaworn S, Lertkhachonsuk AA
J Obstet Gynaecol 2022 Aug;42(6):2331-2335. Epub 2022 Apr 26 doi: 10.1080/01443615.2022.2049724. PMID: 35470751
Personalized cancer treatment for ovarian cancer.
Chumworathayi B
Asian Pac J Cancer Prev 2013;14(3):1661-4. doi: 10.7314/apjcp.2013.14.3.1661. PMID: 23679252
Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials.
Markman M, Webster K, Zanotti K, Peterson G, Kulp B, Belinson J
Gynecol Oncol 2004 Jun;93(3):699-701. doi: 10.1016/j.ygyno.2004.03.023. PMID: 15196867
A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer.
Verschraegen CF, Gupta E, Loyer E, Kavanagh JJ, Kudelka AP, Freedman RS, Edwards CL, Harris N, Steger M, Steltz V, Giovanella BC, Stehlin JS
Anticancer Drugs 1999 Apr;10(4):375-83. doi: 10.1097/00001813-199904000-00005. PMID: 10378672

Clinical prediction guides

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283.
O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C
Gynecol Oncol 2023 Sep;176:16-24. Epub 2023 Jul 5 doi: 10.1016/j.ygyno.2023.06.021. PMID: 37418832Free PMC Article
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD
Br J Cancer 2022 Jun;126(12):1695-1703. Epub 2022 Feb 11 doi: 10.1038/s41416-022-01717-6. PMID: 35149854Free PMC Article
The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy.
Nakamura M, Obata T, Daikoku T, Fujiwara H
Int J Mol Sci 2019 Nov 4;20(21) doi: 10.3390/ijms20215482. PMID: 31689961Free PMC Article
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ
Lancet Oncol 2019 May;20(5):636-648. Epub 2019 Apr 1 doi: 10.1016/S1470-2045(19)30029-4. PMID: 30948273
Exploring the use of chronic low-dose oral etoposide in ovarian cancer: is there a role for this "new drug" in the management of platinum-refractory disease?
Markman M, Hakes T, Reichman B, Barakat R, Curtin J, Jones W, Lewis JL Jr, Rubin S, Almadrones L, Hoskins W
Semin Oncol 1992 Dec;19(6 Suppl 14):25-7. PMID: 1488652

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...